NASDAQ:FNCH Finch Therapeutics Group - FNCH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.35 -0.06 (-13.58%) (As of 03/28/2023 05:23 PM ET) Add Compare Share Share Today's Range$0.32▼$0.3850-Day Range$0.36▼$0.5552-Week Range$0.30▼$5.45Volume567,473 shsAverage Volume169,200 shsMarket Capitalization$16.85 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Finch Therapeutics Group MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4,757.1% Upside$17.00 Price TargetShort InterestHealthy0.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 7 Articles This WeekInsider TradingSelling Shares$1,755 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector182nd out of 1,002 stocksBiological Products, Except Diagnostic Industry30th out of 166 stocks 3.5 Analyst's Opinion Consensus RatingFinch Therapeutics Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Finch Therapeutics Group has a forecasted upside of 4,757.1% from its current price of $0.35.Amount of Analyst CoverageFinch Therapeutics Group has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.57% of the float of Finch Therapeutics Group has been sold short.Short Interest Ratio / Days to CoverFinch Therapeutics Group has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Finch Therapeutics Group has recently decreased by 51.65%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFinch Therapeutics Group does not currently pay a dividend.Dividend GrowthFinch Therapeutics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FNCH. Previous Next 2.8 News and Social Media Coverage News SentimentFinch Therapeutics Group has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Finch Therapeutics Group this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Finch Therapeutics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,755.00 in company stock.Percentage Held by Insiders44.60% of the stock of Finch Therapeutics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.97% of the stock of Finch Therapeutics Group is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Finch Therapeutics Group is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Finch Therapeutics Group is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFinch Therapeutics Group has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Finch Therapeutics Group (NASDAQ:FNCH) StockFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.Read More Receive FNCH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address FNCH Stock News HeadlinesMarch 25, 2023 | msn.comLooking Into Finch Therapeutics Group's Return On Capital EmployedMarch 25, 2023 | finance.yahoo.comFinch Therapeutics Group Full Year 2022 Earnings: Misses ExpectationsMarch 28, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 23, 2023 | finance.yahoo.comFinch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 22, 2023 | americanbankingnews.comFinch Therapeutics Group (NASDAQ:FNCH) versus Atara Biotherapeutics (NASDAQ:ATRA) Head-To-Head ContrastJanuary 24, 2023 | finance.yahoo.comMicrobiome startup cuts 95% of remaining staff in 3rd layoff in 9 monthsJanuary 24, 2023 | marketwatch.comFinch Therapeutics Ending Phase 3 Study, Cutting Most of Workforce >FNCHJanuary 24, 2023 | finance.yahoo.comFinch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other AssetsMarch 28, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. November 11, 2022 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Kezar Life Sciences (KZR), RVL Pharmaceuticals (RVLP)November 11, 2022 | finance.yahoo.comFinch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial ResultsNovember 9, 2022 | finance.yahoo.comFinch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx ConferenceOctober 24, 2022 | finance.yahoo.comFinch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile InfectionOctober 1, 2022 | seekingalpha.comFNCH Finch Therapeutics Group, Inc.September 1, 2022 | finance.yahoo.comAfter Takeda ends collaboration, microbiome startup Finch Therapeutics cuts 50 jobsSeptember 1, 2022 | markets.businessinsider.comFinch Therapeutics To Reduce Workforce - Quick FactsSeptember 1, 2022 | finance.yahoo.comFinch Therapeutics Provides Business UpdateAugust 11, 2022 | finance.yahoo.comFinch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial ResultsAugust 10, 2022 | finance.yahoo.comHere's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn SituationJuly 20, 2022 | nasdaq.comAs Finch Therapeutics Group, Inc.'s market cap (NASDAQ:FNCH) drops to US$103m, insiders might be questioning their decision to buy earlier this yearJuly 20, 2022 | finance.yahoo.comAs Finch Therapeutics Group, Inc. (NASDAQ:FNCH) drops to US$103m market cap, insiders might rethink their US$650k stock purchase earlier this yearJune 2, 2022 | finance.yahoo.comFinch Therapeutics to Participate in Upcoming June Investor ConferencesMay 16, 2022 | finance.yahoo.comFinch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ResultsMay 9, 2022 | finance.yahoo.comFinch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022May 2, 2022 | nz.finance.yahoo.comFinch Therapeutics Group, Inc. (FNCH)April 29, 2022 | finance.yahoo.comWhy Finch Therapeutics Stock Is Skyrocketing TodayApril 20, 2022 | finance.yahoo.comFinch Therapeutics Cuts 20% Workforce, Realigns Focus On C. Diff, Autism ProgramsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FNCH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address FNCH Company Calendar Last Earnings11/10/2021Today3/28/2023Next Earnings (Estimated)5/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FNCH CUSIPN/A CIK1733257 Webwww.finchtherapeutics.com Phone617-229-6499FaxN/AEmployees191Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$17.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+4,757.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,650,000.00 Net Margins-13,315.45% Pretax Margin-13,315.45% Return on Equity-68.64% Return on Assets-48.64% Debt Debt-to-Equity Ratio0.15 Current Ratio5.08 Quick Ratio5.08 Sales & Book Value Annual Sales$860,000.00 Price / Sales19.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book0.18Miscellaneous Outstanding Shares48,150,000Free Float26,672,000Market Cap$16.85 million OptionableNot Optionable Beta-0.01 Key ExecutivesDr. Mark Burnham Smith Ph.D. (Age 35)CEO & Director Comp: $698.66kMr. Marc B. Blaustein C.F.A. (Age 59)CFA, MPP, COO, Principal Financial & Accounting Officer Comp: $378.21kMr. Joseph D. Vittiglio Esq. (Age 50)J.D., Chief Bus. & Legal Officer and Corp. Sec. Comp: $526.08kMr. Bryan Gillis M.B.A.Chief Technology OfficerMr. James S. Sigler (Age 61)Exec. VP of CMC Dr. Howard Franklin M.B.A.M.D., Chief Medical OfficerDr. Alka Batycky Ph.D.Chief Devel. OfficerMore ExecutivesKey CompetitorsInhibikase TherapeuticsNYSE:IKTSQZ BiotechnologiesNYSE:SQZOrganovoNASDAQ:ONVOAIM ImmunoTechNYSE:AIMGenetic TechnologiesNASDAQ:GENEView All CompetitorsInsiders & InstitutionsMarc BlausteinSold 4,619 sharesTotal: $1,755.22 ($0.38/share)MSD Partners L.P.Sold 235,294 shares on 2/15/2023Ownership: 0.320%Millennium Management LLCSold 46,797 shares on 2/15/2023Ownership: 0.155%Renaissance Technologies LLCBought 82,300 shares on 2/13/2023Ownership: 0.257%Marc BlausteinSold 3,636 sharesTotal: $5,054.04 ($1.39/share)View All Insider TransactionsView All Institutional Transactions FNCH Stock - Frequently Asked Questions Should I buy or sell Finch Therapeutics Group stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Finch Therapeutics Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FNCH shares. View FNCH analyst ratings or view top-rated stocks. What is Finch Therapeutics Group's stock price forecast for 2023? 2 equities research analysts have issued twelve-month price objectives for Finch Therapeutics Group's shares. Their FNCH share price forecasts range from $17.00 to $17.00. On average, they expect the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 4,757.1% from the stock's current price. View analysts price targets for FNCH or view top-rated stocks among Wall Street analysts. How have FNCH shares performed in 2023? Finch Therapeutics Group's stock was trading at $0.48 at the start of the year. Since then, FNCH shares have decreased by 27.1% and is now trading at $0.35. View the best growth stocks for 2023 here. Are investors shorting Finch Therapeutics Group? Finch Therapeutics Group saw a decline in short interest in March. As of March 15th, there was short interest totaling 95,000 shares, a decline of 51.7% from the February 28th total of 196,500 shares. Based on an average daily trading volume, of 180,600 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.6% of the company's stock are sold short. View Finch Therapeutics Group's Short Interest. When is Finch Therapeutics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our FNCH earnings forecast. How were Finch Therapeutics Group's earnings last quarter? Finch Therapeutics Group, Inc. (NASDAQ:FNCH) released its earnings results on Wednesday, November, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.21. The firm earned $11.34 million during the quarter. Finch Therapeutics Group had a negative net margin of 13,315.45% and a negative trailing twelve-month return on equity of 68.64%. When did Finch Therapeutics Group IPO? (FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO. What is Finch Therapeutics Group's stock symbol? Finch Therapeutics Group trades on the NASDAQ under the ticker symbol "FNCH." Who are Finch Therapeutics Group's major shareholders? Finch Therapeutics Group's stock is owned by many different institutional and retail investors. Top institutional investors include MSD Partners L.P. (0.32%), Renaissance Technologies LLC (0.26%), Millennium Management LLC (0.15%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jeffery A Smisek, Marc Blaustein and Nicholas Haft. View institutional ownership trends. How do I buy shares of Finch Therapeutics Group? Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Finch Therapeutics Group's stock price today? One share of FNCH stock can currently be purchased for approximately $0.35. How much money does Finch Therapeutics Group make? Finch Therapeutics Group (NASDAQ:FNCH) has a market capitalization of $16.85 million and generates $860,000.00 in revenue each year. The company earns $-114,650,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. How many employees does Finch Therapeutics Group have? The company employs 191 workers across the globe. How can I contact Finch Therapeutics Group? The official website for the company is www.finchtherapeutics.com. The company can be reached via phone at 617-229-6499 or via email at ir@finchtherapeutics.com. This page (NASDAQ:FNCH) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.